Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NovaBay Pharmaceuticals (NBY) Depreciation and Depletion (2016 - 2025)

Historic Depreciation and Depletion for NovaBay Pharmaceuticals (NBY) over the last 8 years, with Q3 2025 value amounting to $1000.0.

  • NovaBay Pharmaceuticals' Depreciation and Depletion changed 0.0% to $1000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $20000.0, marking a year-over-year decrease of 3939.39%. This contributed to the annual value of $40000.0 for FY2024, which is 2156.86% down from last year.
  • As of Q3 2025, NovaBay Pharmaceuticals' Depreciation and Depletion stood at $1000.0, which was down 0.0% from $1000.0 recorded in Q2 2025.
  • NovaBay Pharmaceuticals' 5-year Depreciation and Depletion high stood at $30000.0 for Q1 2022, and its period low was $1000.0 during Q3 2024.
  • Over the past 4 years, NovaBay Pharmaceuticals' median Depreciation and Depletion value was $12000.0 (recorded in 2023), while the average stood at $10166.7.
  • The largest annual percentage gain for NovaBay Pharmaceuticals' Depreciation and Depletion in the last 5 years was 3333.33% (2024), contrasted with its biggest fall of 9230.77% (2024).
  • Over the past 4 years, NovaBay Pharmaceuticals' Depreciation and Depletion (Quarter) stood at $30000.0 in 2022, then tumbled by 60.0% to $12000.0 in 2023, then surged by 33.33% to $16000.0 in 2024, then plummeted by 93.75% to $1000.0 in 2025.
  • Its Depreciation and Depletion was $1000.0 in Q3 2025, compared to $1000.0 in Q2 2025 and $2000.0 in Q1 2025.